WallStSmart

Sandisk Corp (SNDK)vsSanofi ADR (SNY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sanofi ADR generates 423% more annual revenue ($46.72B vs $8.93B). SNY leads profitability with a 16.7% profit margin vs -11.7%. SNY earns a higher WallStSmart Score of 49/100 (D+).

SNDK

Hold

49

out of 100

Grade: D+

Growth: 7.3Profit: 5.0Value: 5.0Quality: 8.0
Piotroski: 4/9Altman Z: 1.82

SNY

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 6.0Value: 4.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for SNDK.

SNYSignificantly Overvalued (-91.3%)

Margin of Safety

-91.3%

Fair Value

$24.58

Current Price

$44.60

$20.02 premium

UndervaluedFair: $24.58Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SNDK5 strengths · Avg: 9.8/10
Operating MarginProfitability
35.5%10/10

Strong operational efficiency at 35.5%

Revenue GrowthGrowth
61.2%10/10

Revenue surging 61.2% year-over-year

EPS GrowthGrowth
618.0%10/10

Earnings expanding 618.0% YoY

Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Market CapQuality
$104.75B9/10

Large-cap with strong market position

SNY3 strengths · Avg: 9.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Market CapQuality
$108.62B9/10

Large-cap with strong market position

Free Cash FlowQuality
$1.59B8/10

Generating 1.6B in free cash flow

Areas to Watch

SNDK4 concerns · Avg: 2.8/10
Price/BookValuation
10.3x4/10

Trading at 10.3x book value

Altman Z-ScoreHealth
1.824/10

Grey zone — moderate risk

Return on EquityProfitability
-9.4%2/10

ROE of -9.4% — below average capital efficiency

Profit MarginProfitability
-11.7%1/10

Currently unprofitable

SNY3 concerns · Avg: 3.0/10
EPS GrowthGrowth
2.4%4/10

2.4% earnings growth

Return on EquityProfitability
6.7%3/10

ROE of 6.7% — below average capital efficiency

PEG RatioValuation
4.322/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : SNDK

The strongest argument for SNDK centers on Operating Margin, Revenue Growth, EPS Growth. Revenue growth of 61.2% demonstrates continued momentum.

Bull Case : SNY

The strongest argument for SNY centers on Price/Book, Market Cap, Free Cash Flow. Profitability is solid with margins at 16.7% and operating margin at 14.3%.

Bear Case : SNDK

The primary concerns for SNDK are Price/Book, Altman Z-Score, Return on Equity.

Bear Case : SNY

The primary concerns for SNY are EPS Growth, Return on Equity, PEG Ratio.

Key Dynamics to Monitor

SNDK profiles as a hypergrowth stock while SNY is a mature play — different risk/reward profiles.

SNDK is growing revenue faster at 61.2% — sustainability is the question.

SNY generates stronger free cash flow (1.6B), providing more financial flexibility.

Monitor COMPUTER HARDWARE industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SNDK scores higher overall (49/100 vs 49/100) and 61.2% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Sandisk Corp

TECHNOLOGY · COMPUTER HARDWARE · USA

Sandisk Corporation (Ticker: SNDK) is a U.S.-based technology company that develops, manufactures, and sells data storage products and solutions built on NAND flash memory technology, including solid-state drives (SSDs), embedded storage, memory cards, and USB flash drives for consumer, enterprise, and cloud computing markets.

Visit Website →

Sanofi ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Want to dig deeper into these stocks?